Wednesday May 23, 2018

Incessant dengue: Figure reaches 21 in capital

0
//
22
Republish
Reprint

By NewsGram Staff Writer

New Delhi: With dengue claiming three more lives on Thursday, the toll in the national capital rose to 21 on Friday.

photo credit: indianexpress.com
photo credit: indianexpress.com

Mohd. Shehwaj (11) from Uttar Pradesh, Kiran Kumari (12) from Delhi’s Nangloi and Rahisha (37) from Dwarka area died on Thursday at Ram Manohar Lohia (RML) Hospital.

Delhi Health Minister Satyender Jain earlier announced that a total of 11 people died of dengue in the city.

“They all died due to dengue shock syndrome leading to multi-organ failure on Thursday,” an RML official said.

In another case, an 18-year-old Rishabh succumbed to the virus at Max Hospital in Vaishali in Ghaziabad on Thursday.

According to Rishab’s family, the Delhi youth was first taken to the Gupta Multispeciality Hospital in Vivek Vihar then to Max Hospital, Patparganj, and finally to Max Hospital, Vaishali, where he died.

“We first took him to Gupta Multispeciality Hospital in Vivek Vihar on Monday, where his platelet count was found to be 80,000. The doctors there told us to arrange five units of platelets. Around 2.30 AM on Monday, the doctors said he was critical and must be shifted to a bigger hospital,” said Rishabh’s elder brother Himangshu.

“… we took him to Max Hospital, Patparganj, early Wednesday where there weren’t enough beds… We then took him to Max in Vaishali around 8.30 p.m. on Wednesday. He was put on ventilator but he died around 6 PM on Thursday,” he added.

A Max hospital statement said: “Rishab was brought to the emergency room of Max Hospital, Patparganj, in a critical condition on September 16 (Wednesday) early morning hours with diagnosis of dengue shock syndrome fever with Thrombocytopenia.”

“On investigation, his platelet count was found very low 9,000 and one unit of platelet was transfused. Since the critical care beds were not available, the option of shifting the patient to nearby Max Vaishali was given to the attendants. In the meantime, patient was managed in the Emergency care of Max Patparganj,” it added.

“With the consent of the attendant, the patient was shifted to Max Vaishali in an advanced cardiac life support ambulance with emergency doctor and a paramedic staff in the evening of 16 September. In spite of all active resuscitation measures put in by the team of doctors, the patient succumbed to dengue on September 17 (Thursday) at 5.55 PM.”

(with inputs from IANS)

Click here for reuse options!
Copyright 2015 NewsGram

Next Story

Dengue Vaccine Should Not Be Used Widely: UN Health Agency

UN Health Agency issued an important statement regarding the dengue vaccine

0
//
23
Dengue vaccine.
A Manila Health officer shows off a pair of vials of the anti-dengue vaccine Dengvaxia after being recalled from local government health centers Tuesday, Dec. 5, 2017 in Manila, Philippines. The World Health Organization says the first-ever vaccine for dengue needs to be dealt with in "a much safer way," meaning that the shot should mostly be given to people who have previously been infected with the disease. VOA

The World Health Organization says the first-ever vaccine for dengue needs to be dealt with in “a much safer way,” meaning that the shot should mostly be given to people who have previously been infected with the disease.

In November, the vaccine’s manufacturer, Sanofi Pasteur, said people who had never been sickened by dengue before were at risk of developing a more serious disease after getting the shot.

After a two-day meeting this week, WHO’s independent vaccines group said it now had proof the vaccine should only be used “exclusively or almost exclusively in people who have already been infected with dengue.”

Also Read: Anti-dengue Antibody Drug May Neutralize Zika Virus

The U.N. health agency said a test should be developed so doctors would be able to quickly tell if people had previously been sickened by dengue – but the group acknowledged doing that so isn’t straightforward.

“We see significant obstacles in using the vaccine this way, but we are confident this also spurs the development of a rapid diagnostic test,” said Dr. Joachim Hombach, executive secretary of WHO’s expert group, during a news conference Thursday.

Representational image for dengue vaccination
Representational image. Wikimedia Commons

Sanofi said last year that doctors should consider whether people might have been previously infected with dengue before deciding whether they should risk getting immunized. The company said it expected to take a 100 million euro ($118 million) loss based on that news.

People who catch dengue more than once can be at risk of a hemorrhagic version of the disease. The mosquito-spread virus is found in tropical and sub-tropical climates across Latin and South America, Asia, Africa and elsewhere. It causes a flu-like disease that can cause joint pain, nausea, vomiting and a rash. In severe cases, dengue can result in breathing problems, hemorrhaging and organ failure.

About half the world’s population is at risk of dengue; WHO estimates that about 96 million people are sickened by the viral infection every year.

Also Read: Dengue fever may increase risk of stroke: Study

Following Sanofi’s announcement last year, the Philippines halted its dengue immunization program, the world’s first national vaccination program for dengue. The government also demanded a refund of more than 3 billion pesos ($59 million) from Sanofi and is considering further legal action.

In February, the Philippines said the vaccine was potentially linked to the deaths of three people: all of them died of dengue despite having received the vaccine.

The country imposed a symbolic fine of $2,000 on Sanofi and suspended the vaccine’s approval, charging that the drugmaker broke rules on how the shot was registered and marketed.

More than 730,000 children aged 9 and above in the Philippines have received at least one dose of the dengue vaccine, usually delivered in three doses.

There is no specific treatment for dengue and there are no other licensed vaccines on the market.  VOA